How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention
Bush, K.; Mobashery, S.
Advances in Experimental Medicine and Biology 456: 71-98
1998
ISSN/ISBN: 0065-2598 PMID: 10549364 Document Number: 486367
Document emailed within 1 workday
Related Documents
Williams, M. 2000: Drug discovery in a new century: mechanistic opportunities and therapeutic challenges Current Opinion in Investigational Drugs 1(1): I-IiiMoland, E.Smith.; Black, J.A.; Hossain, A.; Hanson, N.D.; Thomson, K.S.; Pottumarthy, S. 2003: Discovery of CTX-M-like extended-spectrum beta-lactamases in Escherichia coli isolates from five US States Antimicrobial Agents and ChemoTherapy 47(7): 2382-2383
Wang, W.-p.; Shao, H.-f.; Wang, J.-n.; Zhang, X.-w.; Shi, L.-n. 2006: Genotype distribution of extended-spectrum beta-lactamases and AmpC beta-lactamases produced in Escherichia coli isolated from men with urinary infection Zhonghua Nan Ke Xue 12(11): 1000-1003
Schacter, L.P.; Anderson, C.; Canetta, R.M.; Kelley, S.; Nicaise, C.; Onetto, N.; Rozencweig, M.; Smaldone, L.; Winograd, B. 1992: Drug discovery and development in the pharmaceutical industry Seminars in Oncology 19(6): 613-621
Mulualem, Y.; Kasa, T.; Mekonnen, Z.; Suleman, S. 2012: Occurrence of extended spectrum beta (b)-lactamases in multi-drug resistant Escherichia coli isolated from a clinical setting in Jimma University Specialized Hospital, Jimma, southwest Ethiopia East African Journal of Public Health 9(2): 58-61
Neu, H.C.; Chin, N.X. 1985: A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 4(1): 63-70
Yamaguchi, Y. 2006: Structure-based drug design of the irreversible inhibitors of metallo-beta-lactamases Japanese Journal of Antibiotics 59(1): 51-56
Lee, S.-H.; 임윤택 2015: Identification of Knowledge Driven Production Path through ICTs Industry as a Tool of Knowledge Sharing and Knowledge Management in Knowledge City Journal of The Korean Urban Management Association 28(2): 409-434
Robinson, D.S. 1994: Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling Psychopharmacology Bulletin 30(1): 23-25
Kojima, H.; Okabe, T.; Nagano, T. 2013: Open innovation center for drug discovery: a research-supporting network for drug discovery Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(6): 327-332
Bradford, P.A.; Jacobus, N.V.; Bhachech, N.; Bush, K. 1996: TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases Antimicrobial Agents and ChemoTherapy 40(1): 260-262
Fujita, Y. 2013: Innovation by TaNeDS (Take a New challenge of Drug diScovery) collaborative drug discovery project Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(2): 89-95
Chlebicki, M.P.; Oh, H.M.L. 2004: Extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella spp. in a Singapore hospital: clinical spectrum Annals of the Academy of Medicine Singapore 33(3): 302-306
Sazykin, A.I.; Navashin, S.M. 1984: Substrate specificity of the beta-lactamases found in a number of clinical strains of gram-negative bacteria Antibiotiki 29(9): 657-661
Brown, A.G. 1986: Clavulanic acid, a novel beta-lactamase inhibitor--a case study in drug discovery and development Drug Design and Delivery 1(1): 1-21
She, D.; Liu, Y. 2002: The expression of AmpC and extended-spectrum beta-lactamases among clinical isolates of enterobacter cloacae and its impact on antibiotics susceptibility Zhonghua Yi Xue Za Zhi 82(19): 1355-1358
Bedenić, B.; Singer, S. 2000: Effect of broad spectrum beta-lactamases on in vitro sensitivity of clinical isolates of Klebsiella pneumoniae to oral cephalosporins Lijecnicki Vjesnik 122(1-2): 8-13
Ekşi, F.; Ozer, G.ön.ç; Balci, I. 2007: Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp Mikrobiyoloji Bulteni 41(3): 447-452
Alóz, J.I. 1998: Evolution of resistance to beta-lactam inhibitors of beta-lactamases Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 11(4): 375-376
Malhotra, V.L.; Khandpur, N.; Dass, A.; Mehta, G. 2008: Prevalence of extended spectrum beta-lactamases producing clinical isolates from patients of urinary tract infection in a tertiary care hospital in Delhi Journal of Communicable Diseases 40(4): 269-272